Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
2027. dec. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
2027. jún. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
2027. máj. 15.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
2027. ápr. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
2027. márc. 9.· PHASE3 · RECRUITING· CTGOV
Vizsgálat
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
2027. márc. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
2027. jan. 31.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
HER2 Vaccine for Locally Advanced Breast Cancer
2027. jan. 1.· PHASE1 · RECRUITING· CTGOV
Vizsgálat
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
2026. dec. 15.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
2026. dec. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer
2026. dec. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
2026. nov. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
2026. nov. 30.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
2026. nov. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
2026. nov. 30.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
2026. nov. 11.· NA · RECRUITING· CTGOV
Publikáció
Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 - metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study.
2026. nov. 6.· Breast cancer (Tokyo, Japan)· PUBMED
Publikáció
Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05.
2026. nov. 6.· Future oncology (London, England)· PUBMED
Publikáció
TFAP2A promotes the stemness and metastasis of luminal B/HER2-positive and triple-negative breast cancer cells by enhancing KDM4B transcriptional activity.
2026. nov. 5.· Molecular biology reports· PUBMED
Publikáció
Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer: A Review.
2026. nov. 5.· JAMA oncology· PUBMED
Publikáció
Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies.
2026. nov. 5.· Expert review of anticancer therapy· PUBMED
Publikáció
Agreement Between Medical Laboratory Technologists and Pathologists' Assessment of ERBB2 (HER2) Fluorescence In Situ Hybridization Across Breast and Gastric Scoring Criteria.
2026. nov. 2.· Applied immunohistochemistry & molecular morphology : AIMM· PUBMED
Vizsgálat
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
2026. nov. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
2026. nov. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
2026. nov. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
[Efficacy of sacituzumab govitecan following treatment with trastuzumab deruxtecan in a patient with HR-positive/HER2-low metastatic breast cancer.].
2026. nov. 1.· Recenti progressi in medicina· PUBMED
Publikáció
[CDK4/6 inhibitor to antibody-drug conjugates in HER2-low metastatic breast cancer: sequential therapeutic management of a case report.].
2026. nov. 1.· Recenti progressi in medicina· PUBMED